Ribociclib
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
Ribociclib: From HR+/HER2- Breast Cancer to Myeloid Leukemia
One-Sentence Summary
Ribociclib is a CDK4/6 inhibitor originally developed and marketed globally for hormone receptor-positive, HER2-negative advanced breast cancer, though it is not currently registered in India. The TxGNN model’s top prediction suggests possible relevance to Myeloid Leukemia, but this is currently supported only by 0 clinical trials and 3 publications, one of which actually describes AML as a treatment-related adverse event rather than a therapeutic benefit.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in India regulatory data (drug not marketed); globally approved for HR+/HER2- advanced breast cancer as a CDK4/6 inhibitor |
| Predicted New Indication | Myeloid Leukemia |
| TxGNN Prediction Score | 99.35% |
| Evidence Level | L4 (preclinical/mechanistic study only; no clinical trials) |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for ribociclib is not available in this evidence pack. Based on known information, ribociclib is an oral, highly selective CDK4/6 (cyclin-dependent kinase 4/6) inhibitor; its efficacy in HR+/HER2- metastatic breast cancer has been established through multiple Phase 3 trials, and mechanistically it may be applicable to other proliferative malignancies where the cyclin D–CDK4/6–Rb pathway drives tumor growth.
One preclinical study in the evidence pack (PMID 32560251) explored CDK4/6 inhibitors as a strategy to overcome ABCB1/ABCG2-mediated drug resistance in acute myeloid leukemia (AML) cell lines — providing a plausible, though early-stage, mechanistic rationale for the TxGNN prediction.
However, a second publication in the same evidence set (PMID 30575100) reports a case of AML arising as a complication after CDK4/6 inhibitor treatment, in a patient with underlying clonal hematopoiesis. This is an important countervailing signal: it suggests CDK4/6 inhibition may, in some contexts, be associated with AML as an adverse event rather than as a therapeutic target. The third literature item retrieved (PMID 41641105, a vulvar/breast adenocarcinoma case report) does not appear directly relevant to AML and is likely a low-relevance match. Given this mixed and very limited evidence base, the mechanistic plausibility should be treated as hypothesis-generating only.
Clinical Trial Evidence
Currently no related clinical trials registered for Myeloid Leukemia.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 32560251 | 2020 | Preclinical/Mechanistic | Cancers | CDK4/6 inhibitors evaluated in vitro for overcoming ABCB1/ABCG2-mediated drug resistance in AML cells — supportive but early-stage rationale |
| 30575100 | 2019 | Case Report (adverse event) | American Journal of Hematology | AML with eosinophilia occurring after CDK4/6 inhibitor treatment, linked to underlying clonal hematopoiesis — signals possible risk, not benefit |
| 41641105 | 2026 | Case Report (low relevance) | Frontiers in Oncology | Describes concurrent vulvar and breast adenocarcinoma; does not directly address ribociclib or myeloid leukemia |
India Market Information
Ribociclib currently has 0 registered licenses in India (market status: Not Marketed). No authorization, product, or approved-indication data is available for this market.
Cytotoxicity (Antineoplastic Drug)
Ribociclib is an antineoplastic agent (oral CDK4/6 inhibitor used in breast cancer treatment), so this section applies.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (CDK4/6 inhibitor) |
| Myelosuppression Risk | High — literature evidence consistently documents neutropenia, leukopenia, and thrombocytopenia as the most common hematologic toxicities of CDK4/6 inhibitors, including ribociclib |
| Emetogenicity Classification | Low to moderate (typical for oral targeted kinase inhibitors) |
| Monitoring Items | Complete blood count (CBC) with differential, liver function tests, and ECG/QT interval monitoring (hepatic toxicity and QT prolongation reported in class literature) |
| Handling Protection | Not a conventional cytotoxic agent, but should be handled per institutional hazardous oral oncolytic protocols given mutagenic/teratogenic potential |
Safety Considerations
- Drug Interactions: Ribociclib has a large documented interaction profile (579 total interactions in this dataset). Notable Major-level interactions include Clarithromycin and Dolasetron. Numerous Moderate-level interactions were also identified, including with Metformin, Pioglitazone, Famotidine, Cimetidine, Dexamethasone, and several corticosteroids/laxatives/antiemetics — consistent with ribociclib’s known CYP3A4-mediated and QT-related interaction risk.
No verified key warnings or contraindications data was available in this evidence pack (source data gap); please refer to the package insert for complete safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The Myeloid Leukemia prediction is supported only by one early-stage preclinical study and lacks any clinical trial evidence; a second, directly relevant publication actually reports AML as a possible adverse consequence of CDK4/6 inhibitor therapy rather than a therapeutic benefit. This conflicting signal, combined with the complete absence of clinical trial data, means the evidence does not currently support advancing this indication.
To proceed, the following is needed:
- Resolve the conflicting preclinical vs. adverse-event signal for AML before any further investment (e.g., mechanistic follow-up studies distinguishing therapeutic effect from treatment-emergent hematologic malignancy)
- Obtain ribociclib’s original mechanism of action (MOA) and TFDA/regulatory warning/contraindication data (currently flagged as blocking data gaps, DG001/DG002)
- Note: within this same evidence pack, the Thrombocytopenia prediction (rank 2, score 99.27%) is supported by substantially stronger evidence — 5 clinical trials and ~20 publications — and may warrant separate, prioritized evaluation
- If pursuing the AML hypothesis further, require at least one completed Phase 1/2 trial specifically evaluating ribociclib in AML before upgrading the evidence level
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.